Given that CDK12 maps to the smallest region of amplification of the HER2 amplicon, and recurrent fusions were identified in 13% (6/47) HER2-amplified tumours (Supplementary Table 7), we hypothesized that disruptions involving CDK12 were due to a copy number breakpoint within the amplicon. Here, CDK12 is linked to neoplasm.